reboxetine sold brand name edronax among others drug norepinephrine reuptake inhibitor nri class marketed antidepressant pfizer use treatment major depression although also used offlabel panic disorder attention deficit hyperactivity disorder approved use many countries worldwide approved use united states although effectiveness antidepressant challenged multiple published reports popularity continued much debate whether reboxetine efficacious placebo treatment depression according metaanalysis secondgeneration antidepressants reboxetine effective placebo significantly less effective less acceptable drugs treating acutephase adults unipolar major british mhra said september study several limitations overall balance benefits risks reboxetine remains positive authorised uk europewide review available efficacy safety data confirmed reboxetine benefit placebo authorised indication efficacy clearly shown patients severe severe according systematic review metaanalysis iqwig including unpublished data published data reboxetine overestimated benefit reboxetine versus placebo reboxetine versus ssris also underestimated harm concluding reboxetine ineffective potentially harmful antidepressant study also showed nearly three quarters data patients took part trials reboxetine published systematic review network metaanalysis comparing efficacy acceptability antidepressant drugs concluded reboxetine effective placebo significantly less efficacious antidepressants randomised doubleblind placebocontrolled trial reboxetine significantly improved symptoms panic another randomised controlled trial compared paroxetine reboxetine found paroxetine significantly outperformed reboxetine treatment panic despite discouraging finding openlabel trial examining efficacy reboxetine ssriresistant panic disorder demonstrated significant benefit reboxetine numerous clinical trials provided support efficacy reboxetine treatment attention deficit hyperactivity disorder adhd case series openlabel pilot study demonstrated efficacy reboxetine treating bulimia reboxetine may also efficacy treating therapyresistant paediatric nocturnal pilot study demonstrated efficacy reboxetine treatment individual trials metaanalysis suggest reboxetine attenuate antipsychoticinduced weight evidence benefit depressive possibly symptoms schizophrenia added antipsychotic reboxetine contraindicated narrowangle glaucoma cardiovascular disease epilepsy bipolar disorder urinary retention prostatic hypertrophy hypersensitive reboxetine common incidence adverse effects include insomnia dizziness dry mouth constipation nausea excessive common adverse effects include loss appetite agitation anxiety headache restlessness tingling sensations distorted sense taste difficulty seeing near far problems accommodation fast heart beat heart palpitations relaxing blood vessels leading low blood pressure high blood pressure vomiting rash sensation incomplete bladder emptying urinary tract infection painful difficult urination urinary retention erectile dysfunction ejaculatory pain delay metaanalysis found reboxetine significantly less well tolerated secondgeneration antidepressants compared reboxetine considered relatively lowrisk antidepressant symptoms reliance reboxetine odesethylation markedly inhibited papaverine weakly inhibits reboxetine intermediatelevel inhibitor pglycoprotein gives potential interact ciclosporin tacrolimus paroxetine sertraline quinidine fluoxetine reboxetine fairly selective norepinephrine reuptake inhibitor nri approximately selectivity norepinephrine transporter net serotonin transporter despite selectivity reboxetine slightly inhibit reuptake serotonin therapeutic interact inhibit dopamine transporter reboxetine found inhibit brain cardiac girks characteristic shares nri ssenantiomers reboxetine predominantly metabolized primary metabolite reboxetine odesethylreboxetine also three minor phenol b phenol b reboxetine two chiral centers thus four stereoisomers may exist rr ss rs srisomers active ingredient reboxetine racemic mixture two enantiomers reboxetine discovered farmitaliacarlo erba first published farmitalia first clinical farmitalia acquired pharmacia pharmacia turn acquired pfizer first approved europe provisionally approved fda fda issued pfizer approvable letter based clinical trials fda required issued preliminary approval german institute quality efficiency health care iqehc published results metaanalysis clinical trial data reboxetine acute depression included data subjects pfizer never published mentioned iqehc combed pfizers publications reboxetine approvals determined data missing publication record analysis complete data set yielded result reboxetine effective placebo side effects placebo fluoxetine paper led widespread sharp criticism pfizer stronger calls publication clinical trial edronax brand name reboxetine every englishspeaking country approved clinical use brand names include denotes product longer httpsenwikipediaorgwikireboxetine